XOMA Royalty (XOMA) Asset Utilization Ratio (2011 - 2026)
XOMA Royalty's (XOMA) quarterly Asset Utilization Ratio came in at 0.22 in Q1 2026, up 404.65% year-on-year from 0.04 in Q1 2025, and up 14.1% quarter-over-quarter from 0.19 in Q4 2025.
XOMA Royalty (XOMA) Asset Utilization Ratio (2011 - 2026) Analysis & Trends
XOMA Royalty has disclosed Asset Utilization Ratio across 16 years of filings, most recently posting 0.22 for Q1 2026.
- Asset Utilization Ratio for Q1 2026 came in at 0.22, up 404.65% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.22 (up 404.65% YoY), and the FY2025 annual result was 0.21, up 68.83% from the prior year.
- Asset Utilization Ratio came in at 0.22 for Q1 2026 at XOMA Royalty, up from 0.19 in the prior quarter.
- In the past five years, Asset Utilization Ratio ranged from a high of 0.22 in Q1 2026 to a low of 0.02 in Q4 2023.
- The 5-year median for Asset Utilization Ratio is 0.03 (2022), against an average of 0.05.
- Across the five-year window, Asset Utilization Ratio slumped 86.62% in 2022 and surged 514.63% in 2025, its largest moves.
- XOMA Royalty's Asset Utilization Ratio stood at 0.04 in 2022, then plunged by 49.76% to 0.02 in 2023, then jumped by 49.81% to 0.03 in 2024, then soared by 514.63% to 0.19 in 2025, then rose by 14.1% to 0.22 in 2026.
- The last three Asset Utilization Ratio figures came in at 0.22 (Q1 2026), 0.19 (Q4 2025), and 0.04 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | 0.55 |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 0.60 |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | 1,422.00 |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 0.47 |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | - |
| 10 | XOMA Royalty | 5.52 Mn | -60.56 Mn | - | 0.22 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.22 |
| Dec 31, 2025 | 0.19 |
| Sep 30, 2025 | 0.04 |
| Jun 30, 2025 | 0.04 |
| Mar 31, 2025 | 0.04 |
| Dec 31, 2024 | 0.03 |
| Sep 30, 2024 | 0.04 |
| Jun 30, 2024 | 0.04 |
| Mar 31, 2024 | 0.02 |
| Dec 31, 2023 | 0.02 |
| Sep 30, 2023 | 0.03 |
| Jun 30, 2023 | 0.02 |
| Mar 31, 2023 | 0.02 |
| Dec 31, 2022 | 0.04 |
| Sep 30, 2022 | 0.03 |
| Jun 30, 2022 | 0.03 |
| Mar 31, 2022 | 0.03 |
| Dec 31, 2021 | 0.02 |
| Sep 30, 2021 | 0.22 |
| Jun 30, 2021 | 0.23 |